Med Life SA · BVB:M
Med Life SA — 9M 2021 Earnings Presentation
19 slides from Med Life SA's earnings presentation, Nov 12, 2021
Slide 1: 9m 2021 Financial Results
9m 2021 Financial Results Conference call presentation 12 November, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Snapshot Highlights 9m 2021 • Key messages 9m 2021 • Outlook AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 9m 2021
Highlights 9m 2021 • Snapshot • Key messages 9m 2021 • Outlook 1 4/
Slide 5: Snapshot
Snapshot ➢ Pro-forma consolidated Sales of RON 1,2 bn in 9m 2021, increase by 56.5% compared to 9m 2020; Reported increase is on one hand due to last year`s crisis, but also due to sustained activity in 2021 on the laboratory segment, clinics - especially on the monitoring of patients with chronic p
Slide 6: Key messages 9m 2021
Key messages 9m 2021 All business lines were on an upward trend in the first 9 months of this year, which indicates both a higher concern of Romanians for prevention services mixed with increased preference of patients for medical services and surgeries performed in private hospitals ➢ Clinics: focu
Slide 7: Key messages 9m 2021 (Cont.)
Key messages 9m 2021 (Cont.) ➢ Corporate: developed dedicated programs for the corporate segment, as employers become more and more concerned about the health of their employees; 6.5% increase in revenue, with a portfolio of subscriptions higher by 4% as compared to 9m 2020 (740k HPP). ➢ Pharmacies:
Slide 8: Operational KPIs – supporting annex for BL evolution and bridge to pro-forma figures
Operational KPIs – supporting annex for BL evolution and bridge to pro-forma figures On a pro-forma basis, Clinics remain the main sales unit of the group, with 27% share of total pro-forma consolidated Sales, followed by Hospitals with 25% (which also reflect NeoLife acquisition) and Laboratories w
Slide 9: Key messages 9m 2021 (Cont.)
Key messages 9m 2021 (Cont.) The M&A and development plan was focused on the area of oncology diagnostic and treatment services and we have recently announced the acquisition of two leading medical centers in this field: Neolife Medical Center (RON 92m Sales in 2020) and OncoCard Brasov (RON 56.4m S
Slide 10: Key messages 9m 2021 (Cont.)
Key messages 9m 2021 (Cont.) 1) Neolife Medical Center Bucharest (Baneasa) (2014): mainly equipped with two highly competitive accelerators for Radiotherapy and Radiosurgery, a Brachytherapy system, a strong Nuclear Medicine department (PET-CT and Scintigraphy) and a high-performance Chemotherapy se
Slide 11: Outlook for the end of 2021
Outlook for the end of 2021 ➢ Pro-forma consolidated turnover of over one third of a billion euros ➢ Continue the M&A program: we are in advances discussions for another key transaction, which we hope to announce by the end of this year & plan on another 2-3 M&A transactions. ➢ We have important amb
Slide 12: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 12 /
Slide 13: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 13 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 14: Consolidated Statement of Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) explained 1) 9m 2021 Pro-forma vs. 9m 2020 IFRS ❑ Sales increased by 56.5%, to RON 1.2 bn; ❑ OPEX increased by 52.0%, to RON 1 bn; ❑ Twofold increase in EBIT, to 153.8m RON, leading to 12.7% margin (9.9% same period last year), due to improved financia
Slide 15: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 1.5 p.p. in EBITDA margin due to: ➢ Increase in Commodities with 1.9 p.p. of Sales due to consolidation of CED Pharma starting with 1st July and Pharmachem Distributie starting with 1st August; ➢ Increase in Rent with 0.6 p.p.
Slide 16: Consolidated Statement of Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 16 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 17: Consolidated Statement of Financial Position (2/2)
Consolidated Statement of Financial Position (2/2) Debt position 17 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 18: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance: 1. 1.5 times increase in net cash from operating activities, to 156m RON; 2. 65% engaged in investing activities: 102m RON; 3. Cash from financing activities of 6.8m RON 18 / 1.Highlights 2021 2
Slide 19: Q&A Session Thank you!
Q&A Session Thank you! 3 19 /